Singapore markets close in 5 hours 51 minutes

GILD May 2023 80.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.9600+0.0900 (+4.81%)
As of 02:25PM EST. Market open.
Full screen
Previous close1.8700
Open1.9600
Bid1.9200
Ask2.0500
Strike80.00
Expiry date2023-05-19
Day's range1.9600 - 1.9600
Contract rangeN/A
Volume2
Open interest453
  • Zacks

    Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

    Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.

  • Motley Fool

    Is Gilead Sciences a Good Stock to Buy Now?

    Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations. A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy. Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.

  • Zacks

    Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

    Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.